Novartis – Swiss Quality and Innovations in Healthcare
Novartis
Novartis AG is a Swiss pharmaceutical company headquartered in Basel. It was formed in 1996 through the merger of two Basel companies, Ciba-Geigy and Sandoz. Its shares trade on the SIX Swiss Exchange as part of the SMI index, and its American depositary receipts on the New York Stock Exchange.
In recent years Novartis has concentrated on innovative prescription medicines: it spun off its eye care business Alcon in 2019 and its generics and biosimilars business Sandoz in 2023. Its core areas today are cardiovascular, renal and metabolic diseases, immunology, neuroscience and oncology.
In oncology Novartis is best known for Glivec (imatinib). The FDA approved it for chronic myeloid leukaemia in May 2001, about ten weeks after the application was filed, making it one of the first targeted cancer drugs. Its current portfolio also includes Jakavi (ruxolitinib), a JAK inhibitor for myelofibrosis, polycythaemia vera and graft-versus-host disease developed with Incyte; Kisqali (ribociclib), a CDK4/6 inhibitor for HR-positive, HER2-negative breast cancer, sold in some countries as Kryxana; and Rydapt (midostaurin) for FLT3-mutated acute myeloid leukaemia and systemic mastocytosis.
Beyond oncology, Novartis makes transplant medicines, including Myfortic (mycophenolic acid) to prevent kidney transplant rejection.
Unifarm carries Novartis medicines Glivec 400 (imatinib), Jakavi 5, 15 and 20 (ruxolitinib), Kisqali and Kryxana (ribociclib), Rydapt (midostaurin) and Myfortic (mycophenolic acid).